Büller HR - Search Results

1

Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.

van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Décousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso MA, Büller HR, Raskob GE. van Es N, et al. Among authors: buller hr. Thromb Haemost. 2015 Nov 25;114(6):1268-76. doi: 10.1160/TH15-06-0452. Epub 2015 Aug 13. Thromb Haemost. 2015. PMID: 26271200 Clinical Trial.

2

Direct thrombin inhibitors in acute coronary syndromes: present and future.

Weitz JI, Buller HR. Weitz JI, et al. Among authors: buller hr. Circulation. 2002 Feb 26;105(8):1004-11. doi: 10.1161/hc0802.104331. Circulation. 2002. PMID: 11864933 Review. No abstract available.

3

Treatment of symptomatic venous thromboembolism: improving outcomes.

Büller HR. Büller HR. Semin Thromb Hemost. 2002 Jun;28 Suppl 2:41-8. doi: 10.1055/s-2002-32315. Semin Thromb Hemost. 2002. PMID: 12073179 Review.

4

Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees.

Moons AH, Peters RJ, Cate Ht, Bauer KA, Vlasuk GP, Büller HR, Levi M. Moons AH, et al. Among authors: buller hr. Thromb Haemost. 2002 Oct;88(4):627-31. Thromb Haemost. 2002. PMID: 12362234

5

Travel and the risk of symptomatic venous thromboembolism.

ten Wolde M, Kraaijenhagen RA, Schiereck J, Hagen PJ, Mathijssen JJ, Mac Gillavry MR, Koopman MM, Büller HR. ten Wolde M, et al. Among authors: buller hr. Thromb Haemost. 2003 Mar;89(3):499-505. Thromb Haemost. 2003. PMID: 12624634

6

The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis.

van Dongen CJ, Vink R, Hutten BA, Büller HR, Prins MH. van Dongen CJ, et al. Among authors: buller hr. Arch Intern Med. 2003 Jun 9;163(11):1285-93. doi: 10.1001/archinte.163.11.1285. Arch Intern Med. 2003. PMID: 12796064

7

Quality of life and the duration of treatment with vitamin K antagonists in patients with deep venous thrombosis.

Locadia M, Sprangers MA, de Haes HC, Büller HR, Prins MH. Locadia M, et al. Among authors: buller hr. Thromb Haemost. 2003 Jul;90(1):101-7. Thromb Haemost. 2003. PMID: 12876632 Clinical Trial.

8

Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review.

Klerk CP, Smorenburg SM, Büller HR. Klerk CP, et al. Among authors: buller hr. Arch Intern Med. 2003 Sep 8;163(16):1913-21. doi: 10.1001/archinte.163.16.1913. Arch Intern Med. 2003. PMID: 12963564 Review.

9

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.

Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Büller HR, et al. Ann Intern Med. 2004 Jun 1;140(11):867-73. doi: 10.7326/0003-4819-140-11-200406010-00007. Ann Intern Med. 2004. PMID: 15172900 Clinical Trial.

10

Antithrombotic therapy and cancer.

Di Nisio M, Squizzato A, Klerk CP, Richel DJ, Büller HR. Di Nisio M, et al. Among authors: buller hr. Curr Opin Hematol. 2004 May;11(3):187-91. doi: 10.1097/01.moh.0000130317.18163.83. Curr Opin Hematol. 2004. PMID: 15257019 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

733 results

Search Page